Hosted on MSN6d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
The company is announcing significant redundancies and staff lay-offs in a bid to satisfy its investors, slashing jobs by 73%. Credit: Shutterstock / Andrii Yalanskyi California-based biotech, IGM ...
Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].
Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter ...
The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a placebo, and therefore ...
Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...
On Monday, H.C. Wainwright analyst Andrew Fein adjusted the price target on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) to $87.00 from the previous $90.00, while maintaining a Buy rating on the ...
On Tuesday, BofA Securities adjusted its price target for Denali Therapeutics Inc. (NASDAQ:DNLI) shares, reducing it to $30 from the previous $34, while maintaining a Buy rating on the stock. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback